Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

• Status: Active, not recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: TruDiagnostic
• Treatments: Dasatinib; Quercetin

Criteria

Inclusion Criteria:

• Men and women

• Ages 40 and older

• Patient must be able to comply with treatment plan and laboratory tests

Exclusion Criteria:

• Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision

• No immune system issues or immunodeficiency disease

• No history of viral illness which could be reactivated by immune down regulation

• Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke)

• Diagnosis of a transient ischemic attack in the 6 months prior to screening

• Patients infected with hepatitis, C or HIV

• Patients with Body Mass Index (BMI) > 40 kg/m2

• Presence of active infection 9. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study

• Unable or unwilling to provide required blood sample for testing

• As for the male-participants they are recommended to avoid fertilization for the first 6 months after the clinical trial.

• If the patient has previously used Quercetin and Dasatinib.